Article
The later-line efficacy and safety of immune checkpoint inhibitors plus anlotinib in EGFR-mutant patients with EGFR-TKI-resistant NSCLC: a single-center retrospective study.
Cancer immunology, immunotherapy : CII - 17 May 2024
Yin Xiaoyan, Liu Xinchao, Ren Fei, Meng Xiangjiao
Abstract excerpt
BACKGROUND: Effective treatment after EGFR-TKI resistance is of great clinical concern. We aimed to investigate the efficacy and safety of anlotinib in combination with an anti-PD-1/PD-L1 antibody in later-line therapy for EGFR-mutant NSCLC patients after TKI treatment failure and to explore the independent predictive factors of therapeutic efficacy. METHODS: A total of 71 patients with confirmed advanced...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.